J-Pharma has built its pipeline around amino acid transporter (LAT1)-targeted therapies. What was the vision behind this...
Bispecific antibodies have transformed treatment by simultaneously targeting two molecules, delivering significant clini...
For patients living with a rare disorder, receiving an accurate diagnosis can take years. Misdiagnosis often leads to un...
Although each rare disease affects only a small number of people, collectively they represent one of the world's largest...
BioSpectrum Asia launched the APAC Bioeconomy Index 2026, the first independent, region-native benchmark of Asia-Pacific...
Asia's biopharmaceutical manufacturing sector is entering a new phase of growth, driven by expanding biologics pipelines...
Africa carries the majority of the global sickle cell disease burden, yet care across many health systems remains fragme...
The next generation of cell and gene therapies is pushing manufacturing beyond the limits of conventiona...
As BIO Asia–Taiwan 2026 brought the region’s biotechnology and healthcare ecosystem together in Taip...
How does CT fit into your overall regional expansion strategy, especially in emerging markets like India and Southeast A...
Drug development is approaching a significant inflection point. Advances in induced pluripotent stem cells (iPSCs), orga...
Cell therapy is approaching a defining transition: from highly specialised science to a reproducible, scalable pharmaceu...
The pharmaceutical industry’s innovation equation is changing. Developing an entirely new molecu...
The global CDMO market is moving beyond the era when manufacturing capacity alone defined competitive ...
As BioSpectrum Asia reports on the ground from BIO Asia–Taiwan 2026, being held from July 15–19 in T...
As gene therapy moves from scientific promise towards a new phase of commercial maturity, manufacturing has emerged as o...
Every host city wants the same thing from an event like this: not the visit, but the verdict. What made the press meet w...
There is a particular energy to the first thirty minutes of a conference that knows exactly what it wants to say. As the...
Artificial intelligence is rapidly reshaping the way biopharma companies discover, develop, and manufacture medicines. H...
Advancing Clinical Development and Evidence Generation Clinical development is entering a new era where success depends...
As cell and gene therapies progress from promising research to commercial reality, manufacturing has emerged as ...
As antibody-drug conjugates (ADCs) transition from a promising therapeutic modality to a cornerstone of precision oncolo...
As antibody-drug conjugates (ADCs), bispecific antibodies and other advanced biologics redefine the global therapeutics ...
The rapid expansion of in vivo gene therapy is reshaping expectations for viral vector manufacturing, placing greater em...
ADCs continue to represent a major growth area for drug developers, with the market projected to reach $69B by 20291. As...
